1887

Abstract

Live-vector human immunodeficiency virus (HIV) vaccines are an integral part of a number of HIV vaccine regimens currently under evaluation that have yielded promising results in pre-clinical testing. In this report, a non-pathogenic protozoan parasitic vector, , which shares common target cells with HIV-1, was used to express full-length HIV-1 Gag protein. Immunization of BALB/c mice with recombinant led to the expansion of HIV-1 Gag-specific T cells and stimulated CD8 T cells to produce gamma interferon in response to specific viral Gag epitopes. A booster immunization with recombinant elicited effector memory HIV-1 Gag-specific CD4 T lymphocytes and increased antibody titres against HIV-1 Gag. Most importantly, immunization of human tonsillar tissue cultured with Gag-expressing vaccine vector elicited a 75 % decrease in virus replication following exposure of the immunized tonsils to HIV-1 infection. These results demonstrated that recombinant is capable of eliciting effective immune responses in mice and human systems, respectively, and suggest that this novel non-pathogenic recombinant vaccine vector shows excellent promise as a vaccination strategy against HIV-1.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81995-0
2007-01-01
2019-10-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/1/217.html?itemId=/content/journal/jgv/10.1099/vir.0.81995-0&mimeType=html&fmt=ahah

References

  1. Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A. & Martin, M. A. ( 1986; ). Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59, 284–291.
    [Google Scholar]
  2. Amara, R. R., Villinger, F., Altman, J. D., Lydy, S. L., O'Neil, S. P., Staprans, S. I., Montefiori, D. C., Xu, Y., Herndon, J. G. & other authors ( 2001; ). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69–74.[CrossRef]
    [Google Scholar]
  3. Andersson, E. C., Christensen, J. P., Marker, O. & Thomsen, A. R. ( 1994; ). Changes in cell adhesion molecule expression on T cells associated with systemic virus infection. J Immunol 152, 1237–1245.
    [Google Scholar]
  4. Baba, T. W., Jeong, Y. S., Pennick, D., Bronson, R., Greene, M. F. & Ruprecht, R. M. ( 1995; ). Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267, 1820–1825.[CrossRef]
    [Google Scholar]
  5. Barouch, D. H., Santra, S., Kuroda, M. J., Schmitz, J. E., Plishka, R., Buckler-White, A., Gaitan, A. E., Zin, R., Nam, J.-H. & other authors ( 2001; ). Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 75, 5151–5158.[CrossRef]
    [Google Scholar]
  6. Barouch, D. H., McKay, P. F., Sumida, S. M., Santra, S., Jackson, S. S., Gorgone, D. A., Lifton, M. A., Chakrabarti, B. K., Xu, L. & other authors ( 2003; ). Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77, 8729–8735.[CrossRef]
    [Google Scholar]
  7. Betts, M. R., Ambrozak, D. R., Douek, D. C., Bonhoeffer, S., Brenchley, J. M., Casazza, J. P., Koup, R. A. & Picker, L. J. ( 2001; ). Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses: relationship to viral load in untreated HIV infection. J Virol 75, 11983–11991.[CrossRef]
    [Google Scholar]
  8. Bounou, S., Leclerc, J. E. & Tremblay, M. J. ( 2002; ). Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4+-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J Virol 76, 1004–1014.[CrossRef]
    [Google Scholar]
  9. Breton, M., Tremblay, M. J., Ouellette, M. & Papadopoulou, B. ( 2005; ). Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun 73, 6372–6382.[CrossRef]
    [Google Scholar]
  10. Brun, R. & Schönenberger, M. ( 1979; ). Cultivation and in vitro cloning or procyclic culture forms of Trypanosoma brucei in a semi-defined medium. Acta Trop 36, 289–292.
    [Google Scholar]
  11. Clayton, C. E. ( 2002; ). Life without transcriptional control? From fly to man and back again. EMBO J 21, 1881–1888.[CrossRef]
    [Google Scholar]
  12. DeGrendele, H. C., Estess, P. & Siegelman, M. H. ( 1997; ). Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 278, 672–675.[CrossRef]
    [Google Scholar]
  13. Donnelly, J. J., Wahren, B. & Liu, M. A. ( 2005; ). DNA vaccines: progress and challenges. J Immunol 175, 633–639.[CrossRef]
    [Google Scholar]
  14. Gilbert, P. B., Peterson, M. L., Follmann, D., Hudgens, M. G., Francis, D. P., Gurwith, M., Heyward, W. L., Jobes, D. V., Popovic, V. & other authors ( 2005; ). Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191, 666–677.[CrossRef]
    [Google Scholar]
  15. Glushakova, S., Baibakov, B., Margolis, L. B. & Zimmerberg, J. ( 1995; ). Infection of human tonsil histocultures: a model for HIV pathogenesis. Nat Med 1, 1320–1322.[CrossRef]
    [Google Scholar]
  16. Goulder, P. J. R., Altfeld, M. A., Rosenberg, E. S., Nguyen, T., Tang, Y., Eldridge, R. L., Addo, M. M., He, S., Mukherjee, J. S. & other authors ( 2001; ). Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 193, 181–194.[CrossRef]
    [Google Scholar]
  17. Granucci, F., Feau, S., Zanoni, I., Pavelka, N., Vizzardelli, C., Raimondi, G. & Ricciardi-Castagnoli, P. ( 2003; ). The immune response is initiated by dendritic cells via interaction with microorganisms and interleukin-2 production. J Infect Dis 187 (Suppl. 2), S346–S350.[CrossRef]
    [Google Scholar]
  18. Grivel, J.-C., Biancotto, A., Ito, Y., Lima, R. G. & Margolis, L. B. ( 2003; ). Bystander CD4+ T lymphocytes survive in HIV-infected human lymphoid tissue. AIDS Res Hum Retroviruses 19, 211–216.[CrossRef]
    [Google Scholar]
  19. Harrer, T., Harrer, E., Kalams, S. A., Elbeik, T., Staprans, S. I., Feinberg, M. B., Cao, Y., Ho, D. D., Yilma, T. & other authors ( 1996; ). Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 12, 585–592.[CrossRef]
    [Google Scholar]
  20. Horton, H., Vogel, T. U., Carter, D. K., Vielhuber, K., Fuller, D. H., Shipley, T., Fuller, J. T., Kunstman, K. J., Sutter, G. & other authors ( 2002; ). Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol 76, 7187–7202.[CrossRef]
    [Google Scholar]
  21. Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G. & Schoenberger, S. P. ( 2003; ). CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421, 852–856.[CrossRef]
    [Google Scholar]
  22. Jin, X., Bauer, D. E., Tuttleton, S. E., Lewin, S., Gettie, A., Blanchard, J., Irwin, C. E., Safrit, J. T., Mittler, J. & other authors ( 1999; ). Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189, 991–998.[CrossRef]
    [Google Scholar]
  23. Klenerman, P. & Hill, A. ( 2005; ). T cells and viral persistence: lessons from diverse infections. Nat Immunol 6, 873–879.[CrossRef]
    [Google Scholar]
  24. Letvin, N. L. ( 2005; ). Progress toward an HIV vaccine. Annu Rev Med 56, 213–223.[CrossRef]
    [Google Scholar]
  25. Letvin, N. L., Barouch, D. H. & Montefiori, D. C. ( 2002; ). Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 20, 73–99.[CrossRef]
    [Google Scholar]
  26. MacGregor, R. R., Boyer, J. D., Ugen, K. E., Lacy, K. E., Gluckman, S. J., Bagarazzi, M. L., Chattergoon, M. A., Baine, Y., Higgins, T. J. & other authors ( 1998; ). First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178, 92–100.[CrossRef]
    [Google Scholar]
  27. Margolis, L. B., Fitzgerald, W., Glushakova, S., Hatfill, S., Amichay, N., Baibakov, B. & Zimmerberg, J. ( 1997; ). Lymphocyte trafficking and HIV infection of human lymphoid tissue in a rotating wall vessel bioreactor. AIDS Res Hum Retroviruses 13, 1411–1420.[CrossRef]
    [Google Scholar]
  28. Mashishi, T. & Gray, C. M. ( 2002; ). The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin Chem Lab Med 40, 903–910.
    [Google Scholar]
  29. McConkey, S. J., Reece, W. H. H., Moorthy, V. S., Webster, D., Dunachie, S., Butcher, G., Vuola, J. M., Blanchard, T. J., Gothard, P. & other authors ( 2003; ). Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9, 729–735.[CrossRef]
    [Google Scholar]
  30. McMichael, A. J. & Hanke, T. ( 2003; ). HIV vaccines 1983–2003. Nat Med 9, 874–880.[CrossRef]
    [Google Scholar]
  31. Melief, C. J. M. ( 2003; ). Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur J Immunol 33, 2645–2654.[CrossRef]
    [Google Scholar]
  32. Moore, J. P., Trkola, A., Korber, B., Boots, L. J., Kessler, J. A., II, McCutchan, F. E., Mascola, J., Ho, D. D., Robinson, J. & Conley, A. J. ( 1995; ). A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol 69, 122–130.
    [Google Scholar]
  33. Murphey-Corb, M., Martin, L. N., Davison-Fairburn, B., Montelaro, R. C., Miller, M., West, M., Ohkawa, S., Baskin, G. B., Zhang, J. Y. & other authors ( 1989; ). A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 246, 1293–1297.[CrossRef]
    [Google Scholar]
  34. Norton, J. D. ( 1997; ). Technical tips online. Simple and efficient panning of transfected cell populations expressing a cell surface marker. Trends Genet 13, 41.[CrossRef]
    [Google Scholar]
  35. Papadopoulou, B., Roy, G. & Ouellette, M. ( 1992; ). A novel antifolate resistance gene on the amplified H circle of Leishmania. EMBO J 11, 3601–3608.
    [Google Scholar]
  36. Redfield, R. R., Wright, D. C., James, W. D., Jones, T. S., Brown, C. & Burke, D. S. ( 1987; ). Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 316, 673–676.[CrossRef]
    [Google Scholar]
  37. Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., Racz, P., Tenner-Racz, K., Dalesandro, M. & other authors ( 1999; ). Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283, 857–860.[CrossRef]
    [Google Scholar]
  38. Seaman, M. S., Peyerl, F. W., Jackson, S. S., Lifton, M. A., Gorgone, D. A., Schmitz, J. E. & Letvin, N. L. ( 2004; ). Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J Virol 78, 206–215.[CrossRef]
    [Google Scholar]
  39. Seth, A., Ourmanov, I., Schmitz, J. E., Kuroda, M. J., Lifton, M. A., Nickerson, C. E., Wyatt, L., Carroll, M., Moss, B. & other authors ( 2000; ). Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol 74, 2502–2509.[CrossRef]
    [Google Scholar]
  40. Shedlock, D. J. & Shen, H. ( 2003; ). Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337–339.[CrossRef]
    [Google Scholar]
  41. Whitney, J. B. & Ruprecht, R. M. ( 2004; ). Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis 17, 17–26.[CrossRef]
    [Google Scholar]
  42. Yan, S., Lodes, M. J., Fox, M., Myler, P. J. & Stuart, K. ( 1999; ). Characterization of the Leishmania donovani ribosomal RNA promoter. Mol Biochem Parasitol 103, 197–210.[CrossRef]
    [Google Scholar]
  43. Zhao, C., Papadopoulou, B. & Tremblay, M. J. ( 2004; ). Leishmania infantum promotes replication of HIV type 1 in human lymphoid tissue cultured ex vivo by inducing secretion of the proinflammatory cytokines TNF-α and IL-1α. J Immunol 172, 3086–3093.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81995-0
Loading
/content/journal/jgv/10.1099/vir.0.81995-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error